IDH Mutation, Competitive Inhibition of FTO, and RNA Methylation.
作者信息
Elkashef Sara M, Lin An-Ping, Myers Jamie, Sill Heinz, Jiang Daifeng, Dahia Patricia L M, Aguiar Ricardo C T
机构信息
Division of Hematology and Medical Oncology, Department of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA.
Division of Hematology, Medical University of Graz, A-8036 Graz, Austria.
出版信息
Cancer Cell. 2017 May 8;31(5):619-620. doi: 10.1016/j.ccell.2017.04.001.
Abstract
摘要
相似文献
1
IDH Mutation, Competitive Inhibition of FTO, and RNA Methylation.异柠檬酸脱氢酶（IDH）突变、FTO的竞争性抑制与RNA甲基化
Cancer Cell. 2017 May 8;31(5):619-620. doi: 10.1016/j.ccell.2017.04.001.
2
Methylation of PD-1 Promoter Gene as New Prognostic Marker for IDH Mutant Low-Grade Glioma?PD-1启动子基因甲基化作为IDH突变型低级别胶质瘤的新预后标志物？
EBioMedicine. 2018 Mar;29:9-10. doi: 10.1016/j.ebiom.2018.02.018. Epub 2018 Feb 21.
3
Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.异柠檬酸脱氢酶突变型脑胶质瘤：不断演变的临床和治疗意义。
Cancer. 2017 Dec 1;123(23):4535-4546. doi: 10.1002/cncr.31039. Epub 2017 Oct 5.
4
MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status.MEGF10，一种与神经胶质瘤生存相关的分子特征，可预测 IDH 突变状态。
Dis Markers. 2018 May 20;2018:5975216. doi: 10.1155/2018/5975216. eCollection 2018.
5
Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.端粒酶逆转录酶（TERT）启动子突变对弥漫性胶质瘤中异柠檬酸脱氢酶（IDH）突变和O6-甲基鸟嘌呤-DNA甲基转移酶（MGMT）启动子甲基化的临床意义
Pathol Res Pract. 2018 Jun;214(6):881-888. doi: 10.1016/j.prp.2018.04.002. Epub 2018 Apr 5.
6
Bringing IDH into the Fold.将 IDH 纳入考量。
Cancer Cell. 2016 Feb 8;29(2):139-40. doi: 10.1016/j.ccell.2016.01.010.
7
[IDH mutation on glioma].[胶质瘤中的异柠檬酸脱氢酶（IDH）突变]
Gan To Kagaku Ryoho. 2011 Jun;38(6):937-40.
8
IDH mutation in glioma: new insights and promises for the future.胶质母细胞瘤中的 IDH 突变：新的见解和未来的希望。
JAMA Neurol. 2014 Oct;71(10):1319-25. doi: 10.1001/jamaneurol.2014.1205.
9
DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.2016年世界卫生组织弥漫性胶质瘤分类亚型的DNA甲基化特征
Clin Epigenetics. 2017 Apr 4;9:32. doi: 10.1186/s13148-017-0331-9. eCollection 2017.
10
Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.异柠檬酸脱氢酶突变作为胶质瘤的治疗靶点。
Chin Clin Oncol. 2017 Jun;6(3):33. doi: 10.21037/cco.2017.06.11.
引用本文的文献
1
Dynamic multilayered control of mA RNA demethylase activity.动态多层控制 mA RNA 去甲基化酶活性。
Proc Natl Acad Sci U S A. 2024 Nov 12;121(46):e2317847121. doi: 10.1073/pnas.2317847121. Epub 2024 Nov 4.
2
Abnormal changes in metabolites caused by mA methylation modification: The leading factors that induce the formation of immunosuppressive tumor microenvironment and their promising potential for clinical application.由mA甲基化修饰引起的代谢物异常变化：诱导免疫抑制肿瘤微环境形成的主要因素及其临床应用的潜在前景。
J Adv Res. 2025 Apr;70:159-186. doi: 10.1016/j.jare.2024.04.016. Epub 2024 Apr 25.
3
Insights into the role of RNA mA modification in the metabolic process and related diseases.RNA mA修饰在代谢过程及相关疾病中的作用洞察
Genes Dis. 2023 Jul 4;11(4):101011. doi: 10.1016/j.gendis.2023.04.038. eCollection 2024 Jul.
4
FTO in Lung Cancer: Its Progression and Therapeutic Potential.FTO 在肺癌中的作用：进展与治疗潜力。
Comb Chem High Throughput Screen. 2024;27(15):2301-2307. doi: 10.2174/0113862073281598240227072839.
5
Emerging Roles of Epigenetic Regulators in Maintaining Hematopoietic Stem Cell Homeostasis.表观遗传调控因子在维持造血干细胞稳态中的新兴作用。
Adv Exp Med Biol. 2023;1442:29-44. doi: 10.1007/978-981-99-7471-9_3.
6
Methylation across the central dogma in health and diseases: new therapeutic strategies.甲基化在健康和疾病中的中心法则：新的治疗策略。
Signal Transduct Target Ther. 2023 Aug 25;8(1):310. doi: 10.1038/s41392-023-01528-y.
7
RNA modification: mechanisms and therapeutic targets.RNA修饰：机制与治疗靶点
Mol Biomed. 2023 Aug 24;4(1):25. doi: 10.1186/s43556-023-00139-x.
8
The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches.IDH 突变型急性髓系白血病的奇特案例：生物化学与治疗方法。
Biochem Soc Trans. 2023 Aug 31;51(4):1675-1686. doi: 10.1042/BST20230017.
9
The Regulation of m6A Modification in Glioblastoma: Functional Mechanisms and Therapeutic Approaches.胶质母细胞瘤中m6A修饰的调控：功能机制与治疗方法
Cancers (Basel). 2023 Jun 23;15(13):3307. doi: 10.3390/cancers15133307.
10
RNA modifications in hematological malignancies.血液系统恶性肿瘤中的 RNA 修饰。
Int J Hematol. 2023 Jun;117(6):807-820. doi: 10.1007/s12185-023-03576-0. Epub 2023 Mar 16.
本文引用的文献
1
FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N-Methyladenosine RNA Demethylase.FTO作为一种N-甲基腺苷RNA去甲基化酶在急性髓系白血病中发挥致癌作用。
Cancer Cell. 2017 Jan 9;31(1):127-141. doi: 10.1016/j.ccell.2016.11.017. Epub 2016 Dec 22.
2
Mutant IDH: a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation.突变型异柠檬酸脱氢酶：连接代谢、表观遗传学和转录调控的白血病表型的可靶向驱动因子。
Epigenomics. 2016 Jul;8(7):945-57. doi: 10.2217/epi-2016-0008. Epub 2016 Jul 19.
3
D2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by modulating IDH2.D2HGDH 通过调节 IDH2 来调控α-酮戊二酸水平和双加氧酶功能。
Nat Commun. 2015 Jul 16;6:7768. doi: 10.1038/ncomms8768.
4
The AlkB Family of Fe(II)/α-Ketoglutarate-dependent Dioxygenases: Repairing Nucleic Acid Alkylation Damage and Beyond.依赖于Fe(II)/α-酮戊二酸的双加氧酶的AlkB家族：修复核酸烷基化损伤及其他功能
J Biol Chem. 2015 Aug 21;290(34):20734-20742. doi: 10.1074/jbc.R115.656462. Epub 2015 Jul 7.
5
Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities.致癌性异柠檬酸脱氢酶突变：机制、模型和临床机会。
Cancer Discov. 2013 Jul;3(7):730-41. doi: 10.1158/2159-8290.CD-13-0083. Epub 2013 Jun 24.
Zotero 插件